Sanofi R&D Head John Reed knows how to science
In 2018, the pharma giant Sanofi appointed with John Reed a new R&D head. Apparently Sanofi does not believe in PubPeer.
By Leonid Schneider, on research integrity, biomedical ethics and academic publishing
In 2018, the pharma giant Sanofi appointed with John Reed a new R&D head. Apparently Sanofi does not believe in PubPeer.
Patricia Murray uncovers the business secrets of the Nobelist Martin Evans and his partner Ajan Reginald. It seems the magic iMP cells used to treat patients in Greece were drawn from the blood of patients in Swansea, for the purpose of a secret PhD thesis. There is no serious science behind it, only serious investor money and a fraudulent patent.
German diabetologist Kathrin Maedler is a central figure of a questionable academic dynasty. Using Photoshop simulations, she discovered a cure for diabetes, which was then allegedly validated in clinical trials led by her Swiss PhD advisor Marc Donath. 15 years later, the Maedler-Donath diabetes cure was proven as utterly ineffective by same Donath, in another clinical trial. Maedler’s own PhD student, Amin Ardestani is group leader in Bremen, despite data irregularities and unacknowledged textual reuse in his thesis.
This is a new episode of the data manipulation affair around Weizmann Institute of Science in Rehovot, Israel (and another guestContinue Reading
Five months ago, I reported about data integrity concerns in 6 publications authored by Min-Jean Yin, who had been workingContinue Reading
The science of the fallen star of regenerative medicine Paulo Macchiarini was simple: take a dead organ, strip it ofContinue Reading
Image manipulations are unfortunately a rather widespread practice in biomedical literature, where a large part of research data in figuresContinue Reading
Sonia Melo, Portuguese cancer researcher and recipient of the prestigious EMBO Installation Grant, now has her publications investigated by EMBOContinue Reading





